BioCentury | Oct 10, 2011
Finance

Venture's stress

...Sept 2011 for $325M in cash plus up to $150M in milestones Azelon Pharmaceuticals Inc./ Zelos Therapeutics Inc....
BioCentury | Oct 3, 2011
Company News

Elevation Pharmaceuticals management update

...San Diego, Calif. Business: Pulmonary Hired: Jaisim Shah as SVP and CBO, formerly president of Zelos Therapeutics Inc....
BioCentury | Feb 22, 2010
Company News

Tarsa Therapeutics management update

...Business: Musculoskeletal Hired: David Krause as CMO, formerly CMO, SVP and head of R&D at Zelos Therapeutics Inc. WIR...
BioCentury | Feb 18, 2010
Cover Story

Gut punch to osteoporosis

...serotonin you can induce bone formation" with an oral therapeutic, said Brian MacDonald, CEO of Zelos Therapeutics Inc....
...anabolic response with a non-PTH therapeutic, you could conceivably capture the whole market," said MacDonald. Zelos'...
...Pharmaceuticals Inc. (NASDAQ:NPSP), Bedminster, N.J. Nycomed , Zurich, Switzerland Symphony Icon Inc. , Rockville, Md. Zelos Therapeutics Inc....
BioCentury | Feb 1, 2010
Clinical News

Teriparatide: Phase I started

...formulation of ZT-034 vs. injectable Forteo teriparatide for 7 days in 50 healthy postmenopausal women. Zelos...
...testing (see BioCentury, Oct. 12, 2009). Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Forteo. Zelos Therapeutics Inc....
BioCentury | Jan 21, 2010
Targets & Mechanisms

Oncostatin's LIFR sentence

...signaling without a similar upregulation of OSM-OSMR signaling. Brian MacDonald, CEO of bone disorder company Zelos Therapeutics Inc....
...Brussels, Belgium The Walter and Eliza Hall Institute of Medical Research , Parkville, Victoria, Australia Zelos Therapeutics Inc....
BioCentury | Oct 12, 2009
Clinical News

ZT-034: Phase I started

...vs. Forteo teriparatide from Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) in 16 healthy volunteers. Zelos Therapeutics Inc....
BioCentury | Jul 28, 2008
Clinical News

ZT-031: SPA received

...NYSE:MRK, Whitehouse Station, N.J.). The company has not disclosed a start timeframe for the study. Zelos Therapeutics Inc....
BioCentury | Jun 23, 2008
Company News

Zelos management update

Zelos Therapeutics Inc. , West Conshohocken, Pa. Business: Musculoskeletal, Autoimmune Appointed: Alan Roemer as CFO, formerly VP of investor relations and corporate communications at Pharmasset Inc. WIR Staff...
BioCentury | Apr 21, 2008
Company News

Aegis Therapeutics, Zelos deal

...technology to develop an intranasal version of ZT-031 to treat osteoporosis and other bone diseases. Zelos'...
...to treat osteoporosis. Financial terms were not disclosed. Aegis Therapeutics LLC , San Diego, Calif. Zelos Therapeutics Inc....
Items per page:
1 - 10 of 41
BioCentury | Oct 10, 2011
Finance

Venture's stress

...Sept 2011 for $325M in cash plus up to $150M in milestones Azelon Pharmaceuticals Inc./ Zelos Therapeutics Inc....
BioCentury | Oct 3, 2011
Company News

Elevation Pharmaceuticals management update

...San Diego, Calif. Business: Pulmonary Hired: Jaisim Shah as SVP and CBO, formerly president of Zelos Therapeutics Inc....
BioCentury | Feb 22, 2010
Company News

Tarsa Therapeutics management update

...Business: Musculoskeletal Hired: David Krause as CMO, formerly CMO, SVP and head of R&D at Zelos Therapeutics Inc. WIR...
BioCentury | Feb 18, 2010
Cover Story

Gut punch to osteoporosis

...serotonin you can induce bone formation" with an oral therapeutic, said Brian MacDonald, CEO of Zelos Therapeutics Inc....
...anabolic response with a non-PTH therapeutic, you could conceivably capture the whole market," said MacDonald. Zelos'...
...Pharmaceuticals Inc. (NASDAQ:NPSP), Bedminster, N.J. Nycomed , Zurich, Switzerland Symphony Icon Inc. , Rockville, Md. Zelos Therapeutics Inc....
BioCentury | Feb 1, 2010
Clinical News

Teriparatide: Phase I started

...formulation of ZT-034 vs. injectable Forteo teriparatide for 7 days in 50 healthy postmenopausal women. Zelos...
...testing (see BioCentury, Oct. 12, 2009). Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Forteo. Zelos Therapeutics Inc....
BioCentury | Jan 21, 2010
Targets & Mechanisms

Oncostatin's LIFR sentence

...signaling without a similar upregulation of OSM-OSMR signaling. Brian MacDonald, CEO of bone disorder company Zelos Therapeutics Inc....
...Brussels, Belgium The Walter and Eliza Hall Institute of Medical Research , Parkville, Victoria, Australia Zelos Therapeutics Inc....
BioCentury | Oct 12, 2009
Clinical News

ZT-034: Phase I started

...vs. Forteo teriparatide from Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) in 16 healthy volunteers. Zelos Therapeutics Inc....
BioCentury | Jul 28, 2008
Clinical News

ZT-031: SPA received

...NYSE:MRK, Whitehouse Station, N.J.). The company has not disclosed a start timeframe for the study. Zelos Therapeutics Inc....
BioCentury | Jun 23, 2008
Company News

Zelos management update

Zelos Therapeutics Inc. , West Conshohocken, Pa. Business: Musculoskeletal, Autoimmune Appointed: Alan Roemer as CFO, formerly VP of investor relations and corporate communications at Pharmasset Inc. WIR Staff...
BioCentury | Apr 21, 2008
Company News

Aegis Therapeutics, Zelos deal

...technology to develop an intranasal version of ZT-031 to treat osteoporosis and other bone diseases. Zelos'...
...to treat osteoporosis. Financial terms were not disclosed. Aegis Therapeutics LLC , San Diego, Calif. Zelos Therapeutics Inc....
Items per page:
1 - 10 of 41